| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 本次会议采用现场和通讯表决方式进行表决，经与会董事认真审议，本次会 议形成以下决议： （一）审议并通过《关于公司 2025 年第三季度报告的议案》 经审议，公司董事会一致认为：公司《2025 年第三季度报告》的编制和审 议程序符合相关法律法规和中国证监会、深圳证券交易所的有关规定，报告内容 真实、准确、完整地反映了公司 2025 年第三季度的实际财务状况和经营成果， 不存在虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。具体内容详见公司同日在中国 证监会指定的创业板信息披露网站（巨潮资讯网 www.cninfo.com.cn）上披露的 《2025 年第三季度报告》。 表决结果：7 票赞成，0 票反对，0 票弃权，审议通过。 ...

Group 1 - The core point of the article is that Sanofi Bio reported a revenue of 1.19 billion yuan in the third quarter, representing a year-on-year growth of 13.40%, while net profit decreased by 47.55% [1] - For the first three quarters, the company's revenue reached 3.453 billion yuan, showing a year-on-year increase of 8.52%, but net profit fell by 17.36% to 211 million yuan [1]

三诺生物传感股份有限公司 2025 年第三季度报告 三诺生物传感股份有限公司 2025 年第三季度报告 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 公告编号：2025-079 2025 年 10 月 1 三诺生物传感股份有限公司 2025 年第三季度报告 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-079 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | 非流动性资产处置损益（包括已计提资产减值 ...

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Macroeconomic Information and Commentary - In the first three quarters, China's GDP reached 10,150.36 billion yuan, with a year-on-year growth of 5.2%. The quarterly growth rates were 5.4% in Q1, 5.2% in Q2, and 4.8% in Q3 [3] - From January to September, the industrial added value above designated size grew by 6.2% year-on-year, while fixed asset investment (excluding rural households) was 3,715.35 billion yuan, down 0.5% year-on-year. Private investment decreased by 3.1% [3] - The retail sales of consumer goods totaled 4,197.1 billion yuan, with a year-on-year growth of 3.0% [3] Industry and Company Analysis Medical Consumables Industry - The sixth batch of medical consumables national procurement introduced new regulations, including the concept of "anchor price" for price difference calculation, aiming to stabilize expectations and prevent vicious competition [7][8] - The focus of this procurement includes drug-coated balloons and urological intervention materials, with a trend towards quality competition rather than just low prices [7][8] - High-value consumables companies are gradually digesting the performance pressure from procurement, with recent innovations and overseas business developments expected to provide new growth points [9] - The medical consumables industry is rated as "overweight," with recommendations to focus on companies with rich product lines and high innovation levels [11] In Vitro Diagnostics Industry - Samsung has partnered with Grail to enter the multi-cancer early detection market, investing 783 million yuan (110 million USD) [15] - The IVD market is undergoing a transformation, with challenges from price controls and procurement affecting short-term performance, but long-term growth is anticipated [17] - The IVD industry is rated as "overweight," with a focus on immunodiagnostics and molecular diagnostics sectors [17] Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 0.38% amidst an overall decline in the pharmaceutical sector [19] - A pilot program for disease-based payment for TCM is set to begin, which may enhance the reimbursement for TCM services [23] - The TCM industry is rated as "overweight," with investment recommendations focusing on companies with strong R&D capabilities and unique products [24]

Core Viewpoint - Sanofi Bio's stock experienced a slight increase of 0.10% on October 20, with a trading volume of 92.06 million yuan, indicating a stable market presence [1] Financing Summary - On October 20, Sanofi Bio had a financing buy-in amount of 6.62 million yuan and a financing repayment of 9.63 million yuan, resulting in a net financing outflow of 3.01 million yuan [1] - As of October 20, the total financing and securities lending balance for Sanofi Bio was 405 million yuan, which accounts for 3.77% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company repaid 3,100 shares in securities lending and sold 400 shares on the same day, with a selling amount of 7,652 yuan, while the securities lending balance was 600,700 yuan, which is below the 10th percentile level over the past year [1] Business Overview - Sanofi Bio, established on August 7, 2002, and listed on March 19, 2012, specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic disease detection [2] - The company's main revenue sources include blood glucose monitoring systems (73.29%), diabetes nutrition and care products (6.59%), glycated hemoglobin testing systems (5.03%), blood lipid testing systems (4.14%), blood pressure monitors (4.11%), and iPOCT monitoring systems (3.94%) [2] - For the first half of 2025, Sanofi Bio reported a revenue of 2.26 billion yuan, reflecting a year-on-year growth of 6.12%, while the net profit attributable to shareholders decreased by 8.52% to 181 million yuan [2] Shareholder and Dividend Information - Since its A-share listing, Sanofi Bio has distributed a total of 1.51 billion yuan in dividends, with 344 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders decreased by 5.49% to 15,500, while the average circulating shares per person increased by 5.81% to 29,341 shares [2][3] - Among the top ten circulating shareholders, Ruiyuan Growth Value Mixed A (007119) holds 27.06 million shares, a decrease of 311,700 shares from the previous period, while Hong Kong Central Clearing Limited increased its holdings by 6.32 million shares to 22.37 million shares [3]

Core Viewpoint - The company is focused on accelerating the implementation of its "O+O" new model for diabetes diagnosis and care in China and the United States, while also aiming to develop "blockbuster products" in the CGM and internet healthcare sectors [1] Group 1: Strategic Focus - The company is committed to building a competitive edge in the Continuous Glucose Monitoring (CGM) field and is open to considering mergers and acquisitions (M&A) or strategic investments in companies with key technological capabilities [1] - The company emphasizes the importance of aligning with partners that share its business philosophy and values, indicating a cautious approach to M&A in non-core areas [1] Group 2: Market Opportunities - The company recognizes the broad prospects in its main business areas, particularly in CGM and internet healthcare, and is actively seeking suitable opportunities for growth [1] - The company acknowledges the need for patience in identifying good acquisition targets, highlighting the challenges and costs associated with entering non-core industries [1]

Group 1 - The core viewpoint of the news is that Sanofi Bio's stock performance and financing activities indicate a stable yet cautious market sentiment, with significant trading volume and a notable financing balance [1][2][3] Group 2 - On October 15, Sanofi Bio's stock rose by 0.10%, with a trading volume of 92.0065 million yuan. The financing buy-in amount for the day was 10.379 million yuan, while the financing repayment was 9.5683 million yuan, resulting in a net financing buy-in of 0.8107 million yuan. The total financing and securities balance reached 398 million yuan [1] - The financing balance of Sanofi Bio as of October 15 is 397 million yuan, accounting for 3.60% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1] - In terms of securities lending, Sanofi Bio had no shares repaid on October 15, with 7,000 shares sold short, amounting to 138,000 yuan at the closing price. The remaining short-selling volume was 31,400 shares, with a balance of 619,200 yuan, which is below the 20th percentile of the past year, indicating low short-selling activity [1] Group 3 - Sanofi Bio, established on August 7, 2002, and listed on March 19, 2012, specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic diseases, with a revenue composition primarily from blood glucose monitoring systems (73.29%) [2] - As of June 30, the number of shareholders in Sanofi Bio was 15,500, a decrease of 5.49% from the previous period, while the average circulating shares per person increased by 5.81% to 29,341 shares [2] - For the first half of 2025, Sanofi Bio reported a revenue of 2.264 billion yuan, a year-on-year increase of 6.12%, while the net profit attributable to shareholders decreased by 8.52% to 181 million yuan [2] Group 4 - Sanofi Bio has distributed a total of 1.512 billion yuan in dividends since its A-share listing, with 344 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included notable institutional investors, with the third-largest being Ruiyuan Growth Value Mixed A, holding 27.0572 million shares, a decrease of 311,700 shares from the previous period [3] - Hong Kong Central Clearing Limited ranked fourth among the top shareholders, increasing its holdings by 6.3198 million shares to 22.3693 million shares [3]

Core Viewpoint - The upcoming listing review meeting for Beijing Angrui Microelectronics Technology Co., Ltd. (Angrui Micro) on October 15 signifies a significant step towards its potential listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, raising scrutiny over the rationality of its fundraising efforts [1]. Group 1: Company Overview - Angrui Micro, established in 2012, specializes in RF front-end and wireless communication, offering a diverse range of chip designs including 2G/3G/4G/5G RF front-end chips, wireless connection chips, and analog chips, primarily used in smartphones, automotive electronics, energy storage, industrial applications, high-performance computing, IoT, and wearable technology [2]. Group 2: Fundraising and Investment Projects - The company plans to raise a total of 2.067 billion yuan, with allocations including approximately 1.096 billion yuan for the R&D and industrialization of 5G RF front-end chips and modules, 408 million yuan for RF SoC R&D and industrialization, and 563 million yuan for the construction of its headquarters and R&D center [2]. Group 3: Financial Impact and Profitability - Angrui Micro acknowledges that the implementation of its fundraising projects will lead to an increase in depreciation and amortization expenses; however, the additional annual depreciation will not exceed 1.5% of existing revenue and projected revenue from the fundraising projects, thus having a relatively minor impact on profits [3]. - The company anticipates that the net profit generated from the fundraising projects will be sufficient to offset the impact of the increased depreciation expenses [3]. Group 4: Client Base and Market Position - Major clients for Angrui Micro's RF front-end products include prominent smartphone manufacturers such as Huawei, Xiaomi, Honor, Samsung, and Vivo, while its RF SoC chip products have been adopted by companies like Alibaba, Xiaomi, HP, and others [3]. - The company aims to leverage its established brand advantage and customer base in the RF industry to drive performance growth through the upgrades and introduction of new products [3]. Group 5: R&D Investment Trends - Over recent years, the proportion of R&D investment relative to revenue has shown a declining trend, decreasing from 29.25% in 2022 to 14.94% in 2024, with a slight increase to 16.40% in the first half of 2025 [4]. - The decline in R&D expense ratio is attributed to significant revenue growth, with a year-on-year increase of 83.62% in 2023 and a further 23.98% in 2024, while the absolute scale of R&D investment remains stable when excluding stock payment factors [4].

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, particularly focusing on innovative drugs and the recovery of left-side sectors as the biggest investment opportunities for the year [5][14]. Core Insights - The innovative drug sector is expected to continue its upward trend, with BD (business development) activities anticipated to catalyze market movements. The upcoming ESMO conference (October 17-21) is highlighted as a key event for clinical data disclosures from domestic innovative drug companies [2][13]. - The report emphasizes the importance of recent Nobel Prize discoveries related to peripheral immune tolerance, which are relevant to the development of new therapies in oncology and autoimmune diseases. This underscores the significance of innovation in these fields [40][50]. - The report notes that the CXO industry in China is entering a recovery phase, with improvements expected in industry orders, capacity utilization, and performance metrics due to enhanced domestic investment and financing data [2][5]. Summary by Sections Innovative Drugs - The innovative drug sector has seen a recent pullback, but the long-term upward trend remains intact. The report suggests that the market is awaiting further BD catalysts and highlights the importance of upcoming clinical data from the ESMO conference [2][13]. - The report indicates that the overall sentiment in the innovative drug sector is still positive, with a focus on potential breakthroughs in cancer and autoimmune therapies following the recent Nobel Prize discoveries [40][50]. Biologics - Novo Nordisk announced an agreement to acquire Akero for $4.7 billion, with Akero's FGF21 analog EFX showing promise as a leading therapy for metabolic dysfunction-related fatty liver disease (MASH) [3][51]. - The report suggests that EFX is the only drug in Phase 2 trials demonstrating significant fibrosis regression in F4 patients, highlighting the need for continued attention to developments in this area [51][57]. Medical Devices - The commercialization of innovative products is accelerating, with domestic replacements making significant progress. For instance, MicroPort's Tumi laparoscopic surgical robot has surpassed 100 global orders and is leading the domestic market share [4][58]. - The report notes that the Tumi robot has received market access in over 60 countries and regions, with a strong presence in high-end markets such as Europe [60][62]. Traditional Chinese Medicine - There has been a continuous increase in new drug IND and NDA applications for traditional Chinese medicine, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [3][64]. - The report highlights ongoing policy support for traditional Chinese medicine, which is expected to drive further innovation and development in this sector [64][65].